Digoxin: Clinical highlights: A review of digoxin and Its use in contemporary medicine

Critical Pathways in Cardiology

Volumn 10, Issue 2, 2011, Pages 93-98

  Ehle, Michael ^a   Patel, Chandni ^a   Giugliano, Robert P ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b TIMI Study Office   (United States)

Author keywords

atrial fibrillation; digoxin; heart failure; therapeutic drug monitoring; toxicity

Indexed keywords

ALPRAZOLAM; AMIODARONE; ANTACID AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; DIGOXIN; DIPHENOXYLATE; DRONEDARONE; IMMUNOGLOBULIN; ITRACONAZOLE; MACROLIDE; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PHENYTOIN; PROPAFENONE; PROTEINASE INHIBITOR; QUINIDINE; RANOLAZINE; RIFAMPICIN; SALAZOSULFAPYRIDINE; SIMVASTATIN; SPIRONOLACTONE; TETRACYCLINE; THYROID HORMONE; UNINDEXED DRUG; VERAPAMIL;

ABDOMINAL PAIN; ANOREXIA; ATRIOVENTRICULAR DISSOCIATION; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; BLURRED VISION; CLINICAL PRACTICE; CONFUSION; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; FATIGUE; HALLUCINATION; HEADACHE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART PALPITATION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; LEAN BODY WEIGHT; NAUSEA; PHARMACODYNAMICS; PR INTERVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; ST SEGMENT DEPRESSION; VISUAL DISORDER; VOMITING;

ATRIAL FIBRILLATION; CARDIOTONIC AGENTS; CLINICAL PROTOCOLS; DIGOXIN; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; DRUG TOXICITY; HEART FAILURE; HEART RATE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL CONTRACTION;

EID: 79959893643     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0b013e318221e7dd     Document Type: Review

References (19)

1. Gheorhgiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation. 2006; 113:2556-2564. (Pubitemid 43948035)
2. Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109L:2959-2964. (Pubitemid 38808316)
3. Product Information: Lanoxin, digoxin 2006. Greenville, NC: GlaxoSmith-Kline; 2006.
4. Heart Failure Society Of America. Heart failure society of America (HFSA) 2006 comprehensive heart failure practice guidelines. J Card Fail. 2006;12: 10-38.
5. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178-186. (Pubitemid 43069034)
6. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2006;48:e149-e246.
7. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Eng J Med. 1993;329:1-7. (Pubitemid 23182871)
8. Uretsky BF, Young JB, Shahidi FE, et al. for the PROVED Investigative Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED Trial. J Am Coll Cardiol. 1993;22:955-962. (Pubitemid 23285742)
9. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. NEJM. 1997;336:525-533.
10. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: The Ancillary Digitalis Investigation Group Trial. Circulation. 2006;114:397-403. (Pubitemid 44264821)
11. Rathore SS, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871-878. (Pubitemid 37430346)
12. Bauman JL, Didomenico RJ, Galanter WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs. 2006;6:1-12.
13. Fenner KS, Troutman MD, Kempshall S, et al. Drug-drug interactions mediated through p-glycoprotein: Clinical relevance and in vitro-in vivo correlation using digosin as a probe drug. Clin Pharmacol Therap. 2009;85: 173-181.
14. Product Information. Verapamil 2007. Corona, CA: Watson Laboratories; 2007.
15. Product Information. Amiodarone 2009. Hawthorne, NY: Taro Pharmaceuticals; 2009.
16. Prescribing Information: Multaq (dronedarone) 2009. Bridgewater, NJ: Sanofi-aventis; 2009.
17. Hassan W, Al-Sergani H, Mourad W, et al. Amyloid heart disease: New frontiers and insights in pathophysology, diagnosis, and management. Tex Heart Inst J. 2005;32:178-184. (Pubitemid 40800126)
18. Prescribing Information: Digibind (digoxin immune Fab) 2003. Research Triangle Park, NC: GlaxoSmithKline; 2003.
19. Prescribing Information: Digifab (digoxin immune Fab) 2005. Brentwood, TN: Protherics Inc; 2005.